VIR BIOTECHNOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.23 USD | +7.86% |
|
+3.52% | -18.19% |
| Apr. 26 | Cytokinetics Appoints Sung Lee as CFO | MT |
| Apr. 18 | Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,379 | 3,411 | 5,480 | 3,369 | 1,353 | 1,118 | - | - |
| Enterprise Value (EV) 1 | 995.8 | 2,675 | 4,707 | 999 | -159.3 | 352 | 429.7 | 645.1 |
| P/E ratio | -2.18 x | -10.7 x | 10.6 x | 6.61 x | -2.19 x | -1.96 x | -2.07 x | -2.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 170 x | 44.7 x | 5 x | 2.09 x | 15.7 x | 27.6 x | 26.9 x | 18.5 x |
| EV / Revenue | 123 x | 35 x | 4.3 x | 0.62 x | -1.85 x | 8.68 x | 10.3 x | 10.7 x |
| EV / EBITDA | -5.74 x | -9.17 x | 11 x | 1.19 x | 0.24 x | -0.62 x | -0.81 x | -1.31 x |
| EV / FCF | -7.19 x | -13.5 x | -67.8 x | 0.63 x | 0.2 x | -0.69 x | -0.84 x | -1.24 x |
| FCF Yield | -13.9% | -7.38% | -1.47% | 160% | 503% | -146% | -118% | -80.7% |
| Price to Book | - | - | - | 1.62 x | 0.85 x | 1.02 x | 1.27 x | 2.77 x |
| Nbr of stocks (in thousands) | 109,679 | 127,389 | 130,880 | 133,116 | 134,521 | 135,844 | - | - |
| Reference price 2 | 12.58 | 26.78 | 41.87 | 25.31 | 10.06 | 8.230 | 8.230 | 8.230 |
| Announcement Date | 3/26/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.091 | 76.37 | 1,095 | 1,616 | 86.18 | 40.56 | 41.59 | 60.53 |
| EBITDA 1 | -173.5 | -291.5 | 426.6 | 839.9 | -664.9 | -564.3 | -532.2 | -491.3 |
| EBIT 1 | -178 | -297 | 420.8 | 833.1 | -684.3 | -602.9 | -588.7 | -575.7 |
| Operating Margin | -2,199.72% | -388.88% | 38.41% | 51.56% | -794.04% | -1,486.28% | -1,415.75% | -951.06% |
| Earnings before Tax (EBT) 1 | -174.5 | -298.6 | 549.8 | 754.3 | -628.2 | -554.5 | -587.8 | -607.9 |
| Net income 1 | -174.7 | -298.7 | 528.6 | 515.8 | -615.1 | -570.6 | -584.8 | -597.3 |
| Net margin | -2,158.98% | -391.09% | 48.25% | 31.92% | -713.69% | -1,406.8% | -1,406.34% | -986.73% |
| EPS 2 | -5.760 | -2.510 | 3.960 | 3.830 | -4.590 | -4.201 | -3.969 | -3.429 |
| Free Cash Flow 1 | -138.6 | -197.5 | -69.41 | 1,595 | -800.4 | -513.6 | -508.9 | -520.6 |
| FCF margin | -1,712.67% | -258.6% | -6.34% | 98.73% | -928.71% | -1,266.25% | -1,223.81% | -860.11% |
| FCF Conversion (EBITDA) | - | - | - | 189.94% | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | 309.25% | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 103.6 | 812.7 | 1,232 | -40.63 | 374.6 | 49.41 | 62.96 | 3.797 | 2.639 | 16.79 | 11.71 | 9.065 | 9.349 | 12.51 | 40.1 |
| EBITDA 1 | -52.03 | 573.3 | 1,015 | -223.9 | 196.5 | -148.5 | -137.9 | -214.2 | -182.3 | -134.5 | -122.7 | -141.4 | -143.8 | -130.8 | - |
| EBIT 1 | -53.38 | 571.8 | 1,014 | -225.2 | 195 | -150.5 | -143.4 | -215.2 | -186.7 | -139 | -155.8 | -153.7 | -160.5 | -150.8 | - |
| Operating Margin | -51.52% | 70.35% | 82.26% | 554.34% | 52.05% | -304.6% | -227.73% | -5,667.26% | -7,075.86% | -828.12% | -1,330.26% | -1,695.76% | -1,716.27% | -1,205.85% | - |
| Earnings before Tax (EBT) 1 | 110.8 | 545.9 | 921.9 | -233.7 | 217.7 | -151.6 | -143.2 | -197.6 | -166.6 | -120.8 | -140.6 | -137.9 | -139.8 | -136.2 | - |
| Net income 1 | 110.4 | 525.3 | 518.6 | -76.49 | 175.3 | -101.6 | -140.9 | -194.8 | -163.4 | -116 | -144.4 | -143.6 | -146.5 | -143 | - |
| Net margin | 106.57% | 64.63% | 42.08% | 188.27% | 46.81% | -205.63% | -223.8% | -5,129.71% | -6,192.23% | -690.85% | -1,232.72% | -1,583.95% | -1,567.17% | -1,142.93% | - |
| EPS 2 | 0.8200 | 3.920 | 3.850 | -0.5800 | 1.300 | -0.7600 | -1.060 | -1.450 | -1.220 | -0.8600 | -1.072 | -1.061 | -1.080 | -1.039 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/24/22 | 5/5/22 | 8/9/22 | 11/3/22 | 2/23/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/22/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 383 | 737 | 773 | 2,370 | 1,513 | 766 | 688 | 473 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -139 | -197 | -69.4 | 1,595 | -800 | -514 | -509 | -521 |
| ROE (net income / shareholders' equity) | -63% | -52.4% | 49.2% | 29.4% | -33.5% | -39.8% | -54% | -74.8% |
| ROA (Net income/ Total Assets) | -49.6% | -41.7% | 36.8% | 21.7% | -26.1% | -30.9% | -38.1% | -43.1% |
| Assets 1 | 351.8 | 715.4 | 1,437 | 2,378 | 2,361 | 1,846 | 1,536 | 1,386 |
| Book Value Per Share 2 | - | - | - | 15.60 | 11.80 | 8.030 | 6.490 | 2.970 |
| Cash Flow per Share 2 | - | -1.600 | -0.3600 | 12.30 | - | -3.240 | -2.800 | - |
| Capex 1 | 8.94 | 6.55 | 21.8 | 68 | 21.6 | 33 | 35 | 37 |
| Capex / Sales | 110.49% | 8.58% | 1.99% | 4.21% | 25.03% | 81.35% | 84.16% | 61.13% |
| Announcement Date | 3/26/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
8.23
USD
Average target price
29.5
USD
Spread / Average Target
+258.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.19% | 1.12B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- VIR Stock
- Financials Vir Biotechnology, Inc.
